Keybank National Association OH Raises Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Keybank National Association OH increased its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 101.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,585 shares of the medical device company’s stock after acquiring an additional 8,853 shares during the quarter. Keybank National Association OH’s holdings in DexCom were worth $1,368,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of DXCM. Farther Finance Advisors LLC lifted its holdings in shares of DexCom by 79.1% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,568 shares of the medical device company’s stock valued at $172,000 after purchasing an additional 1,134 shares during the last quarter. Van ECK Associates Corp grew its stake in DexCom by 14.0% during the 3rd quarter. Van ECK Associates Corp now owns 20,191 shares of the medical device company’s stock worth $1,463,000 after buying an additional 2,475 shares during the last quarter. QRG Capital Management Inc. increased its position in DexCom by 8.6% during the 3rd quarter. QRG Capital Management Inc. now owns 15,697 shares of the medical device company’s stock valued at $1,052,000 after buying an additional 1,248 shares in the last quarter. Comprehensive Financial Consultants Institutional Inc. raised its stake in DexCom by 13.5% in the third quarter. Comprehensive Financial Consultants Institutional Inc. now owns 7,334 shares of the medical device company’s stock valued at $492,000 after buying an additional 874 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in DexCom in the third quarter worth about $222,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 2.1 %

Shares of NASDAQ:DXCM opened at $77.84 on Friday. The company has a market capitalization of $30.42 billion, a PE ratio of 54.43, a PEG ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The business has a 50 day moving average of $84.83 and a two-hundred day moving average of $76.96. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on DXCM. Canaccord Genuity Group upped their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Wells Fargo & Company upped their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Citigroup lifted their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday. Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Finally, Baird R W upgraded DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $99.82.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the sale, the chief operating officer now directly owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 38,083 shares of company stock valued at $3,309,794 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.